Common fragile sites are specific regions in the human genome that are particularly prone to genomic instability under conditions of replicative stress. Recent data suggest that these sites depend on the checkpoint kinase ATR to maintain their stability.
. More recently, Mec1, a homolog of ATR in Saccharomyces cerevisiae, was found to be important for maintenance of genomic stability [8] . In this study, specific chromosomal regions known as 'replication slow zones' were found to replicate more slowly than other regions and become prone to chromosome breakage when Mec1 is lost. This raises the possibility that replication slow zones are analogous to common fragile sites, and taken together with the earlier observations suggests that ATR may play a role in stabilizing fragile sites.
Recently, Casper et al. examined a possible role for ATR in the expression of common fragile sites. Taking advantage of ATR-deficient cells, siRNA techniques and a dominant negative ATR mutant, they found that absence of ATR function increased the average number of chromosome breaks induced by low doses of aphidicolin by 10-20 fold, depending on the method used. Moreover, using specific probes they found that the number of breaks at three individual common fragile sites increased by a similar degree. These results indicate that the observed increase in fragile site expression is not due to a global defect in genomic stability. Perhaps even more significant, the authors found that expression of fragile sites increased when ATR function was lost even in the absence of aphidicolin. Similar to the chromosomal fragmentation observed in ATR-deficient blastocysts, this observation argues that ATR may be needed to stabilize these regions in the absence of extrinsic threats to the genome.
These results provide the first evidence that expression of common fragile sites is actively prevented by ATR. But how loss of ATR leads to abnormalities at these sites is not known. At least two models for ATR's role in this process are possible. One model suggests that ATR is required to prevent cell cycle progression until normal DNA replication is completed ( Figure 1A How might the formation of these structures be related to the expression of fragile sites? It is thought that fragile sites arise from the presence of singlestranded gaps or breaks at susceptible loci during mitosis. Thus, if extensive regions of single-stranded DNA accumulate at stalled replication forks in ATRdeficient cells as they do in Rad53-deficient cells, fragile sites might be observed upon progression into mitosis either from breakage of the DNA or from the persistence of single-stranded gaps in the mitotic chromosomes. Alternatively, structures similar to the reversed forks seen in Rad53-deficient yeast could be responsible for fragile site expression in mammalian cells lacking ATR if these structures are processed into double-strand breaks that persist in mitosis. In fact, studies in E. coli and yeast suggest that reestablishment of a replication fork from a reversed fork structure can be accomplished in one of two ways, one of which could lead to a double-strand break [11, 12] .
The first, non-recombinogenic, process involves the action of a helicase, which by regression of the reversed fork could reestablish the replication fork without strand cleavage, thus preventing a potential genomic rearrangement. The second, recombinogenic, process is based on the similarity of the reversed fork to a Holliday junction (HJ), a key intermediate in the process of homologous recombination. In this scenario, the reversed fork would be cleaved by a HJ resolvase or similar endonuclease to generate a double-strand break. At this point strand invasion would be necessary for replication restart.
The generation of a double-strand break in the context of replication could be dangerous, and it has been hypothesized that when replication forks stall, Rad53, through the action of Mec1, may act to prevent the formation of reversed forks or promote their resolution through helicase action rather than cleavage of the Holliday junction [11, 12] . By analogy then, ATR could be acting to direct the processes of DNA repair and replication restart, effectively preventing potentially dangerous forms of DNA repair from occurring during DNA replication and promoting safer alternatives.
The recent results from Brown and Baltimore seem to favor the second model shown in Figure 1 . In this study, aphidicolin induced a significant increase in H2AX phosphorylation in synchronized ATR-deficient cells, but not wild-type cells, within one hour of treatment. Since H2AX phosphorylation is a marker for doublestrand breaks, the findings indicate that double-strand breaks are formed rapidly in ATR-deficient cells upon aphidicolin treatment. Notably, it was necessary to remove the aphidicolin from the ATR-deficient cells in order for the cells to move into mitosis, where the breaks could be observed directly. This fact indicates that loss of ATR did not lead to mitosis in the presence of unreplicated DNA, and is consistent with a model in which breaks can occur prior to mitosis. Together these results suggest that a replication checkpoint is still intact in this ATR-deficient cell line, but that genomic stability has been compromised.
Clearly more experiments are required to definitively distinguish between these two models or a combination of the two. By definition, a fragile site is a cytogenetic abnormality observed in mitosis. Yet the observation of a fragile site in a mitotic cell does not give any 
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Fragile site expression insight into the timing or nature of the molecular events that lead to its expression. Now that we know that fragile site expression can result from ATR loss, we can ask which function of ATR is critical for this phenotype. We can also ask when the phenotypic defect actually occurs. In this sense, the ability to look at H2AX phosphorylation is extremely useful, as it allows one to observe breaks at any time in the cell cycle. It will now be important to determine if the observed breaks actually occur at fragile sites during S phase. Many additional questions arise from these studies. For example, it will be of significant interest to identify the targets of ATR involved in fragile site stabilization. It will also be important to determine whether there is a general correlation between fragile sites and loss of other checkpoint proteins. In this context, it is interesting that loss of MSH2 and BRCA2, two DNA repair proteins, leads to an increased frequency in the inactivation of one particular common fragile site [14, 15] . In any event, the results of these studies provide more credence to the idea that ATR, like its homologs in yeast, plays a crucial role in maintaining genomic stability.
